Silencing Apoe with divalent‐siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.13703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Chantal M Ferguson und 14 weiteren Autor:innen. Beteiligte Einrichtung: RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIH HHS, NINDS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION The most significant genetic risk factor for late‐onset Alzheimer's disease (AD) is APOE4 , with evidence for gain‐ and loss‐of‐function mechanisms. A clinical need remains for therapeutically relevant tools that potently modulate APOE expression. METHODS We optimized small interfering RNAs (di‐siRNA, GalNAc) to potently silence brain or liver Apoe and evaluated the impact of each pool of Apoe on pathology. RESULTS In adult 5xFAD mice, siRNAs targeting CNS Apoe efficiently silenced Apoe expression and reduced amyloid burden without affecting systemic cholesterol, confirming that potent silencing of brain Apoe is sufficient to slow disease progression. Mechanistically, silencing Apoe reduced APOE‐rich amyloid cores and activated immune system responses. DISCUSSION These results establish siRNA‐based modulation of Apoe as a viable therapeutic approach, highlight immune activation as a key pathway affected by Apoe modulation, and provide the technology to further evaluate the impact of APOE silencing on neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
- Department of Psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
- Luxembourg Centre for Systems Biomedicine (LCSB), Esch-sur-Alzette, Luxembourg.
ORCID-Profile: Chantal M Ferguson
Förderung
- NIA NIH HHS
- NIH HHS
- NINDS NIH HHS
- ODCDC CDC HHS
- NIGMS NIH HHS
- Norfolk Southern
Zitieren
APA
Ferguson, C. M., Hildebrand, S., Godinho, B. M. D. C., Buchwald, J., Echeverria, D., Coles, A., Grigorenko, A., Vangjeli, L., Sousa, J., McHugh, N., Hassler, M., Santarelli, F., Heneka, M. T., Rogaev, E., & Khvorova, A. (2024). Silencing Apoe with divalent‐siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13703
Vancouver
Ferguson CM, Hildebrand S, Godinho BMDC, Buchwald J, Echeverria D, Coles A, et al. Silencing Apoe with divalent‐siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease. Alzheimer's & Dementia. 2024. doi:10.1002/alz.13703
BibTeX
@article{Ferguson2024,
author = {Ferguson, Chantal M and Hildebrand, Samuel and Godinho, Bruno M D C and Buchwald, Julianna and Echeverria, Dimas and Coles, Andrew and Grigorenko, Anastasia and Vangjeli, Lorenc and Sousa, Jacquelyn and McHugh, Nicholas and Hassler, Matthew and Santarelli, Francesco and Heneka, Michael T and Rogaev, Evgeny and Khvorova, Anastasia},
title = {Silencing Apoe with divalent‐siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.13703}
}
EUVIMED